AKR7A3

Across TCGA pan-cancer cohorts, AKR7A3 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of AKR7A3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where AKR7A3 RNA is repressed in tumor relative to normal tissue. In most cancer types AKR7A3 is over-expressed in tumor, although a few such as KIRP and THCA show the opposite, repressed pattern.

KIRP, THCA, and LIHC are the cancer types where AKR7A3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AKR7A3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	III,IV	−3.084	<.001	11	view →
THCA	Male	All	−0.768	<.001	9	view →
LIHC	All	II,III,IV	−2.609	<.001	8	view →
LUAD	Male	II,III,IV	+2.330	<.001	8	view →
KIRC	Male	All	−1.412	<.001	8	view →
LUSC	Female	All	+0.773	<.001	7	view →
KICH	All	All	−2.351	<.001	6	view →
BRCA	All	All	+1.408	<.001	6	view →
CHOL	All	All	−4.376	<.001	5	view →
BLCA	Male	All	+0.648	.009	5	view →
COAD	Female	All	−0.716	.007	4	view →
UCEC	All	All	+0.556	.025	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

AKR7A3–KIRP

Open the KIRP breakdown →